Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Article Article scientifique Article Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy eng 2023-11-23 author Ghasemi Ali Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. author Martinez-Usatorre Amaia 0000-0002-3416-1529 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. author Li Luqing Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. author Hicham Mehdi 0000-0002-9979-4757 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. 402634 Département de pathologie et immunologie (PATIM) author Guichard Alan 0000-0001-8623-9570 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. author Marcone Rachel Agora Cancer Research Center, Lausanne, Switzerland.,Translational Data Science (TDS) Facility, Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland. author Fournier Nadine 0000-0002-9347-7929 Agora Cancer Research Center, Lausanne, Switzerland.,Translational Data Science (TDS) Facility, Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland. 982766 Services communs de la faculté de médecine (SCMU) author Torchia Bruno Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. author Martinez Bedoya Darel 0000-0002-1603-5801 Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.,Center for Translational Research in Onco-Hematology, University of Geneva (UNIGE), Geneva, Switzerland. 932040 Département de médecine (DEMED) author Davanture Suzel Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.,Center for Translational Research in Onco-Hematology, University of Geneva (UNIGE), Geneva, Switzerland. 982947 Département de médecine (DEMED) author Fernández-Vaquero Mirian Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. author Fan Chaofan Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. author Janzen Jakob Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. author Mohammadzadeh Yahya Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. author Genolet Raphael Ludwig Institute for Cancer Research, Lausanne, Switzerland.,Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Switzerland. author Mansouri Nahal Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.,Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. author Wenes Mathias 0000-0001-8478-8592 Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.,Center for Translational Research in Onco-Hematology, University of Geneva (UNIGE), Geneva, Switzerland. 983986 Département de médecine (DEMED) author Migliorini Denis 0000-0003-0151-3222 Agora Cancer Research Center, Lausanne, Switzerland.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.,Center for Translational Research in Onco-Hematology, University of Geneva (UNIGE), Geneva, Switzerland.,Department of Oncology, Geneva University Hospital (HUG), Geneva, Switzerland. 838158 Département de médecine (DEMED) author Heikenwalder Mathias 0000-0002-3135-2274 Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.,The M3 Research Center, Eberhard Karls University, Tübingen, Germany.,Cluster of Excellence iFIT (EXC 2180), Eberhard Karls University, Tübingen, Germany. author De Palma Michele 0000-0001-9128-5459 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. michele.depalma@epfl.ch.,Agora Cancer Research Center, Lausanne, Switzerland. michele.depalma@epfl.ch.,Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. michele.depalma@epfl.ch. 10.1038/s43018-023-00668-y 37996514 2662-1347 https://www.nature.com/articles/s43018-023-00668-y Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation, trafficking and function. Monocyte-derived DCs pulsed with tumor antigens have been tested extensively for therapeutic vaccination in cancer, with mixed clinical results. Here, we present a cell-therapy platform based on mouse or human DC progenitors (DCPs) engineered to produce two immunostimulatory cytokines, IL-12 and FLT3L. Cytokine-armed DCPs differentiated into conventional type-I DCs (cDC1) and suppressed tumor growth, including melanoma and autochthonous liver models, without the need for antigen loading or myeloablative host conditioning. Tumor response involved synergy between IL-12 and FLT3L and was associated with natural killer and T cell infiltration and activation, M1-like macrophage programming and ischemic tumor necrosis. Antitumor immunity was dependent on endogenous cDC1 expansion and interferon-? signaling but did not require CD8<sup>+</sup>T cell cytotoxicity. Cytokine-armed DCPs synergized effectively with anti-GD2 chimeric-antigen receptor (CAR) T cells in eradicating intracranial gliomas in mice, illustrating their potential in combination therapies. Dewey 616 European Commission Extracellular Vesicle-Internalizing Receptors (EVIRs) for Cancer ImmunoGeneTherapy 725051 EVOLVE EU H2020 European Commission Cellular and molecular mechanisms of metabolic immune activation triggering non-alcoholic steatohepatitis (NASH) and HCC 683000 HepatoMetaboPath EU H2020 Swiss Cancer League KLS-4505-08-2018 Swiss National Science Foundation Role of extracellular vesicles in chemotherapy-induced metastasis 188868 CH Projects EVIR Therapeutics Fondation pour la lutte contre le cancer Helmholtz Future topic Inflammation and Immunology Rainer-Hoenig foundation Swiss Institute for Experimental Cancer Research—ISREC Foundation Anita and Werner Damm-Etienne Foundation Association Frédéric Fellay 56 Département de médecine 221 false 1310 Tumeurs cérébrales 1016 0a6434c9-7972-44ea-8708-82e501660dc7 Biomedical Data Science Facility 1462 Contrôle métabolique de l'immunité 1072 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228014 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228161 Nature cancer f748f333-693b-4945-a0a9-4a4bfb769112 Article (Published version) Public Ghasemi Nature Cancer 2023.pdf 17760671 application/pdf CC BY-4.0 ef00e451789e0797664767bbb04c3eb560b23b297654b6b14c3dff7c61ce50c8 e507c360-a944-411a-982c-6583cfdfab72 Appendix Public 43018_2023_668_MOESM1_ESM.pdf 6980335 application/pdf Supplementary Figs. 1–7 and Supplementary Table 1 9c0031fbc4768750a4f52e8ad771207a0200cadb53fb686850f67ee42bcb68ee b57f0e27-3a26-4d7b-b00d-d41b1c4e978a Appendix Public 43018_2023_668_MOESM2_ESM.pdf 11408225 application/pdf Reporting summary 7a6ae0ef18e59c54a8ff59db6e6d00dee617fb4e3fe4041a7527ab8522145915 064b2760-c586-470e-906b-af9835877d8d Supplemental data Public 43018_2023_668_MOESM3_ESM.xlsx 15007 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 1 2e4c61be1b2bb37be80c9f1aa6679c1d7f7f1ea2d48bab48485cf60627c0f339 1d9fa395-11dc-4ed4-a534-e0870e307094 Supplemental data Public 43018_2023_668_MOESM4_ESM.xlsx 27618 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 2 531dfd5c11cbf3025621dc4bd149f42add3caf5222eeaf6b49c921f3a5534d9b 3e875da0-119d-4d53-be84-6074d17cae71 Supplemental data Public 43018_2023_668_MOESM5_ESM.xlsx 34905 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 3 62fac2af08ec1831ad23fd7b01cd0f8413b8b1c00046ca6437224076bf2b8613 2228fa66-43d1-4c54-b29c-f3f747a4c353 Supplemental data Public 43018_2023_668_MOESM6_ESM.xlsx 28475 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 4 77d42d76e6c8a3feb7664ac34d8a84740a16a8b53dcac9df3ff60bf4c3fb76f3 9b1f3c8e-be60-42bd-939d-808e178ed9ea Supplemental data Public 43018_2023_668_MOESM7_ESM.xlsx 20469 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 5 801cf16d1cc06f0e30f86102bc02247ac9c4038c956b73de8bb2257f3f2e2b28 97c3257d-1b62-4227-ac94-dd113f7442ba Supplemental data Public 43018_2023_668_MOESM8_ESM.xlsx 20505 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 6 321f46904190d53aa182fe0c96e0954ecd2e269af6607ad40b8136f0dcfbca0e 0c5d78c2-330b-4983-b3e9-6da853b3aa06 Supplemental data Public 43018_2023_668_MOESM9_ESM.xlsx 29012 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 7 43ce952c78766024a24e848cdec6a412181c3ac008cb8f2faf97024aba4b1eac 357ce741-6f01-473e-a55e-30466a7c1e54 Supplemental data Public 43018_2023_668_MOESM10_ESM.xlsx 14146 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Statistical Source Data Fig. 8 13c13b44dfa1932203377123a8ec9b717b5428d1c2871dd238895e551ae616a8 60704e27-b37f-4d25-b848-163e28a6debd Supplemental data Public 43018_2023_668_MOESM11_ESM.xlsx 10659 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 1 5bdc9aa7e60e6095d5ec44bf4772562265a96b12013e7a0bd44bdfc71eae6438 658791f5-e37d-47a2-8f56-ef359cbdfdd6 Supplemental data Public 43018_2023_668_MOESM12_ESM.xlsx 16745 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 2 729ff44d03cfacbcc914229c83a1388c505a1f2eb23a530ad4f56c5c897835d9 ecad818f-292d-4aaa-8f8f-baade692a280 Supplemental data Public 43018_2023_668_MOESM13_ESM.xlsx 11311 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 3 355adb521d5576772c27434882522548c7603a96cb24d715ff5b3b6da0613097 9774f4d5-dba1-4009-a73c-74af8170156f Supplemental data Public 43018_2023_668_MOESM14_ESM.xlsx 15763 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 4 550ce7ef7f33492bdad980508d06ac3d9f55c697f1dddca560c3c55b0cf29065 ce061cd2-12ec-4a27-aaf3-ccbd160c53f1 Supplemental data Public 43018_2023_668_MOESM15_ESM.xlsx 17459 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 5 e4004c2796e95a9ae76826b0c25006b85790f88a41d4d4c878b9cb785ae2df83 93863607-8e4c-44a2-b33e-39bba4899231 Supplemental data Public 43018_2023_668_MOESM16_ESM.xlsx 24357 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 6 05f2369db2674a3a05ca44a3c53847ad4ae2ebc052867898fbe123edefd4228e 0dee44bd-a431-4fcf-9e2e-c6dc478b5aac Supplemental data Public 43018_2023_668_MOESM17_ESM.xlsx 24320 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 7 23af8198e269ac1ae54a8c5804a2bbb3803c26ad9807d815208760041fcc19fd 7a791038-a717-4906-b6c8-d16d9bbadae5 Supplemental data Public 43018_2023_668_MOESM18_ESM.xlsx 23972 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 8 f6d5e734d9056a7d6c437ad48aa8dc069d8b1f26d6cd8af0806e40684a38b524 25fbc1cd-430c-4b09-8d0c-22aff47ba823 Supplemental data Public 43018_2023_668_MOESM19_ESM.xlsx 15630 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 9 ba2c705484f20b6b0570fc7acf0663823d6e26dc3cc13c19c630d38e8c2cdcad fcaec61d-ad6e-41ab-b8cc-01afa15f4500 Supplemental data Public 43018_2023_668_MOESM20_ESM.xlsx 13712 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source Data Extended Data Fig. 10 24aeaf684019bcbec3e58bbce7f567f8b28515da747d20bcd8c8c5f00ccc330c openAccess Faculté de médecine / Section de médecine clinique / Département de médecine

Title	Published in	Year	Views	Downloads

PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma	Cancer immunology research	2024	302	298
PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma		2023	244	547
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy	Nature cancer	2023	329	353

Archive ouverte UNIGE

Davanture, Suzel